- Conditions
- Glioblastoma Multiforme
- Interventions
- MGMTP140K-encoding retroviral vector, O6-benzylguanine, temozolomide, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Other + 2 more
- Lead sponsor
- Stanton Gerson MD
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 2,571
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Myeloid Malignancy
- Interventions
- azacitidine
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Bortezomib, Total-Body Irradiation, Melphalan, Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Laboratory Biomarker Analysis
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Lymphoma
- Interventions
- IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Berkeley, California + 30 more
- Conditions
- Sickle Cell Disease
- Interventions
- αβ+ T-cell depletion with Miltenyi CliniMACS system
- Device
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- Peripheral Blood Stem Cell Transplantation
- Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV
- Interventions
- Enfuvirtide
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Plasma Cell Leukemia
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test
- Procedure · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 10
- States / cities
- New Haven, Connecticut • North Haven, Connecticut • Baton Rouge, Louisiana + 7 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
- Drug · Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 58 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Graft vs Host Disease
- Interventions
- Atorvastatin calcium (Lipitor)
- Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- AML, MDS
- Interventions
- TSC-101, Control
- Drug · Other
- Lead sponsor
- TScan Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 26
- States / cities
- Gilbert, Arizona • Scottsdale, Arizona • Duarte, California + 21 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- CD33KO-HSPC; CART33
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2044
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic Graft-versus-host Disease
- Interventions
- Rituximab
- Drug
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Severe Hepatic Veno-Occlusive Disease
- Interventions
- Defibrotide
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 22
- States / cities
- Duarte, California • Palo Alto, California • Denver, Colorado + 19 more
- Conditions
- Acute Myeloid Leukemia, Minimal Residual Disease Negativity
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Etoposide, Laboratory Biomarker Analysis
- Procedure · Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 69 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim, Fludarabine, Granulocyte Colony-Stimulating Factor, Thiotepa
- Biological · Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Sarcoma
- Interventions
- educational intervention, informational intervention, internet-based intervention, questionnaire administration, study of socioeconomic and demographic variables, survey administration, psychosocial assessment and care, quality-of-life assessment, standard follow-up care
- Other · Procedure
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 2 Months to 18 Years
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 6
- States / cities
- Duarte, California • Boston, Massachusetts • Cincinnati, Ohio + 3 more
- Conditions
- Multiple Myeloma
- Interventions
- BI-505, High dose melphalan, Autologous stem cell transplantation
- Biological · Other
- Lead sponsor
- BioInvent International AB
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hematopoietic/Lymphoid Cancer
- Interventions
- Allogenic T cell-depleted hematopoietic stem cell transplantation
- Biological
- Lead sponsor
- Leland Metheny
- Other
- Eligibility
- Up to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia, Myelodysplastic Syndromes, Severe Congenital Neutropenia
- Interventions
- alemtuzumab, busulfan, cyclosporine, fludarabine phosphate, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 2
- States / cities
- San Francisco, California • Madison, Wisconsin
- Conditions
- Vitamin D Deficiency, Hematopoietic Stem Cell Transplantation (HSCT)
- Interventions
- Oral Thin Film (OTF) Cholecalciferol (Vitamin D3)
- Dietary Supplement
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Bone Marrow Transplant (BMT)
- Interventions
- Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
- Other
- Lead sponsor
- Ossium Health, Inc.
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Detroit, Michigan • Columbus, Ohio + 1 more
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Breast Cancer
- Interventions
- filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, thiotepa, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2013
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Duarte, California